CD8A and neoplasm: Compared to unmodified conventional IL-2, bempegaldesleukin leads to more CD8+ T cell and NK cell activation/expansion and less Treg expansion and is, thus, hypothesized to have increased anti-tumor activity and reduced toxicities [46].